Bayer Aktiengesellschaft (BAYRY) Projected to Post Earnings on Tuesday

Key Points

• Bayer Aktiengesellschaft is set to release its quarterly earnings on August 5th, with analysts forecasting earnings of $0.23 per share and revenue of $10.79 billion.
• The company recently reported a 0.65 EPS for the previous quarter, exceeding expectations, while maintaining a negative net margin of 7.26%.
• Bayer's stock has experienced a 2.5% decline, with its current share price at $8.35, amid upgrades and downgrades in analyst ratings from various brokerages.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) is anticipated to release its earnings data before the market opens on Tuesday, August 5th. Analysts expect Bayer Aktiengesellschaft to post earnings of $0.23 per share and revenue of $10.79 billion for the quarter. Bayer Aktiengesellschaft has set its FY 2025 guidance at EPS.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported $0.65 earnings per share for the quarter, topping analysts' consensus estimates of $0.63 by $0.02. Bayer Aktiengesellschaft had a negative net margin of 7.26% and a positive return on equity of 13.94%. The firm had revenue of $15.27 billion for the quarter, compared to the consensus estimate of $13.39 billion. On average, analysts expect Bayer Aktiengesellschaft to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Bayer Aktiengesellschaft Price Performance

Shares of Bayer Aktiengesellschaft stock traded up $0.35 during trading hours on Friday, reaching $8.09. The company's stock had a trading volume of 1,020,104 shares, compared to its average volume of 795,780. The firm has a 50 day moving average price of $7.75 and a 200-day moving average price of $6.63. Bayer Aktiengesellschaft has a one year low of $4.79 and a one year high of $8.65. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.25 and a quick ratio of 0.79. The stock has a market cap of $31.79 billion, a P/E ratio of -8.79 and a beta of 0.86.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Hsbc Global Res upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a report on Wednesday, June 11th. Kepler Capital Markets raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research report on Wednesday, June 11th. The Goldman Sachs Group raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research report on Thursday, June 5th. Finally, Wall Street Zen cut shares of Bayer Aktiengesellschaft from a "buy" rating to a "hold" rating in a research report on Saturday, July 26th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Bayer Aktiengesellschaft presently has a consensus rating of "Buy".

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.